[go: up one dir, main page]

RU2010114001A - Применение пептида в качестве терапевтического средства - Google Patents

Применение пептида в качестве терапевтического средства Download PDF

Info

Publication number
RU2010114001A
RU2010114001A RU2010114001/15A RU2010114001A RU2010114001A RU 2010114001 A RU2010114001 A RU 2010114001A RU 2010114001/15 A RU2010114001/15 A RU 2010114001/15A RU 2010114001 A RU2010114001 A RU 2010114001A RU 2010114001 A RU2010114001 A RU 2010114001A
Authority
RU
Russia
Prior art keywords
disease
diseases
pharmaceutical composition
phe
val
Prior art date
Application number
RU2010114001/15A
Other languages
English (en)
Inventor
Дориан БЕВЕК (DE)
Дориан БЕВЕК
Фабио КАВАЛЛИ (CH)
Фабио КАВАЛЛИ
Вера КАВАЛЛИ (CH)
Вера КАВАЛЛИ
Геральд БАХЕР (DE)
Геральд БАХЕР
Original Assignee
Мондобайотек Лабораториз Аг (Li)
Мондобайотек Лабораториз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мондобайотек Лабораториз Аг (Li), Мондобайотек Лабораториз Аг filed Critical Мондобайотек Лабораториз Аг (Li)
Publication of RU2010114001A publication Critical patent/RU2010114001A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)

Abstract

1. Применение пептида Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из инфекции Streptococus pneumoniae, связанных с инфекцией Streptococus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекции синусов и ушей, острого синусита, отита среднего уха, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса головного мозга. ! 3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 5. Фармацевтическая композиция, содержащая пептид Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора. ! 7. Фармацевтическая композиция по п.5 или 6, пригодная для

Claims (9)

1. Применение пептида Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из инфекции Streptococus pneumoniae, связанных с инфекцией Streptococus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекции синусов и ушей, острого синусита, отита среднего уха, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса головного мозга.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
RU2010114001/15A 2007-09-11 2008-09-09 Применение пептида в качестве терапевтического средства RU2010114001A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07017754.8 2007-09-11
EP07017754 2007-09-11

Publications (1)

Publication Number Publication Date
RU2010114001A true RU2010114001A (ru) 2011-10-20

Family

ID=40085520

Family Applications (8)

Application Number Title Priority Date Filing Date
RU2010113987/15A RU2010113987A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ BFGF 1-24 И НЕОБЯЗАТЕЛЬНО (Arg 8) ВАЗОПРЕССИНА ДЛЯ ЛЕЧЕНИЯ, НАПРИМЕР, ИНФЕКЦИИ S. PNEUMONIAE
RU2010113964/15A RU2010113964A (ru) 2007-09-11 2008-09-09 Применение соматостатина-14 в качестве терапевтического средства
RU2010114021/15A RU2010114021A (ru) 2007-09-11 2008-09-09 Субстанция р и тиролиберин для терапевтического применения
RU2010113975/15A RU2010113975A (ru) 2007-09-11 2008-09-09 (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113965/10A RU2010113965A (ru) 2007-09-11 2008-09-09 Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства
RU2010113983/15A RU2010113983A (ru) 2007-09-11 2008-09-09 Применение туфтсина в качестве терапевтического средства
RU2010114033/15A RU2010114033A (ru) 2007-09-11 2008-09-09 Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv
RU2010114001/15A RU2010114001A (ru) 2007-09-11 2008-09-09 Применение пептида в качестве терапевтического средства

Family Applications Before (7)

Application Number Title Priority Date Filing Date
RU2010113987/15A RU2010113987A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ BFGF 1-24 И НЕОБЯЗАТЕЛЬНО (Arg 8) ВАЗОПРЕССИНА ДЛЯ ЛЕЧЕНИЯ, НАПРИМЕР, ИНФЕКЦИИ S. PNEUMONIAE
RU2010113964/15A RU2010113964A (ru) 2007-09-11 2008-09-09 Применение соматостатина-14 в качестве терапевтического средства
RU2010114021/15A RU2010114021A (ru) 2007-09-11 2008-09-09 Субстанция р и тиролиберин для терапевтического применения
RU2010113975/15A RU2010113975A (ru) 2007-09-11 2008-09-09 (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113965/10A RU2010113965A (ru) 2007-09-11 2008-09-09 Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства
RU2010113983/15A RU2010113983A (ru) 2007-09-11 2008-09-09 Применение туфтсина в качестве терапевтического средства
RU2010114033/15A RU2010114033A (ru) 2007-09-11 2008-09-09 Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv

Country Status (8)

Country Link
US (8) US8211856B2 (ru)
EP (8) EP2205261A1 (ru)
JP (7) JP2010538994A (ru)
KR (7) KR20100058547A (ru)
AU (8) AU2008303928A1 (ru)
CA (8) CA2699264A1 (ru)
RU (8) RU2010113987A (ru)
WO (19) WO2009039980A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2528094C2 (ru) * 2012-08-03 2014-09-10 Татьяна Георгиевна Емельянова Средство пептидной структуры, обладающее анальгетическим, противовоспалительным действием, и лекарственные формы на его основе

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
AU2008303896A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP5771006B2 (ja) 2007-12-20 2015-08-26 コーニンクレッカ フィリップス エヌ ヴェ ケースベースの意思決定支援のための方法及び装置
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
WO2009137880A1 (en) 2008-05-14 2009-11-19 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
WO2011047287A1 (en) * 2009-10-15 2011-04-21 Immuneregen Biosciences, Inc. Methods of treating inflammatory and fibrotic lung diseases with substance p analogs
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
US9855320B2 (en) * 2011-10-06 2018-01-02 Chung-Ang University Industry-Academic Cooperation Foundation Angiogenin for treatment of glaucoma
US9044433B2 (en) 2011-10-06 2015-06-02 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US10272133B2 (en) 2011-10-06 2019-04-30 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
KR101327663B1 (ko) * 2011-10-07 2013-11-14 중앙대학교 산학협력단 안지오제닌의 신규 용도
CN102973926A (zh) * 2011-11-20 2013-03-20 上海市肺科医院 胸腺肽α1在制备治疗肺纤维化药物中的用途
CN108653715A (zh) * 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
EP2824106B1 (en) 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
RU2507212C3 (ru) * 2012-03-28 2022-05-04 Общество С Ограниченной Ответственностью "Айвикс" Способ получения рекомбинантного пептида и полученный пептид
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104470943B (zh) 2012-07-03 2017-07-14 一洋药品株式会社 新肽及其用途
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
CA2883791A1 (en) * 2012-09-04 2014-03-13 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
US10046021B2 (en) 2013-02-05 2018-08-14 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
ES2995333T3 (en) 2013-02-05 2025-02-10 Tpcera Ltd Phosphorylcholine conjugates and uses thereof
WO2020056250A1 (en) * 2018-09-14 2020-03-19 Vanderbilt University Methods and compositions for treating skin diseases
US11571455B2 (en) * 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
US12060396B2 (en) 2013-04-11 2024-08-13 Vanderbilt University Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis
US9492544B2 (en) 2013-04-11 2016-11-15 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
CN113413456A (zh) * 2013-05-28 2021-09-21 Ovb(爱尔兰)有限公司 用于生产重组肽的方法及所得到的肽
CN103613643B (zh) * 2013-12-04 2015-04-22 南京晓庄学院 一种生物活性小肽、其合成方法及其作为畜禽饲料添加剂的用途
WO2015179490A1 (en) * 2014-05-21 2015-11-26 Stemnion, Inc. Treatment of diseases and conditions caused by increased vascular permeability
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
DE102015201100B4 (de) * 2015-01-22 2018-05-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Antivirale Mittel
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
RU2626002C1 (ru) 2016-10-24 2017-07-21 Общество С Ограниченной Ответственностью "Айвикс" Новая группа пептидов для лечения женской сексуальной дисфункции
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
AU2018227737B2 (en) 2017-03-01 2021-04-01 Chengdu Huitai Biomedicine Co., Ltd. Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
EP3427756A1 (en) 2017-07-14 2019-01-16 Universidad Autónoma De Barcelona (UAB) Therapeutic nanoconjugates and uses thereof
EP3717504A4 (en) * 2017-11-27 2021-10-20 The University of Hong Kong YEATS INHIBITORS AND METHOD OF USING
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
WO2019199704A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
CN113164552B (zh) * 2018-10-04 2025-06-06 新泽西州立罗格斯大学 使用神经介素肽减少2型细胞因子介导的炎症的方法
CN112386678B (zh) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 多肽或其衍生物的应用
WO2021119218A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022149159A1 (en) * 2021-01-05 2022-07-14 Jaya Shukla Molecular imaging complex for positron emission tomography
MX2023009463A (es) 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.
CN115747214B (zh) * 2022-07-12 2025-11-18 安徽理工大学 Mlph基因在制备治疗尘肺病药物中的应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4041155A (en) * 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4100271A (en) 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
US4125605A (en) * 1977-10-19 1978-11-14 The United States Government Method of employing oral TRH
EP0035454A3 (en) * 1980-02-28 1982-03-03 Genentech, Inc. Desacetylthymosin alpha 1, its process of preparation and its use
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US4874744A (en) * 1989-03-13 1989-10-17 University Of Cincinnati Method of using melanocyte stimulating hormone as dermatis treatment
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5256396A (en) 1990-01-24 1993-10-26 Colgate-Palmolive Company Topical composition
JP3130080B2 (ja) * 1990-12-27 2001-01-31 日清製粉株式会社 ペプチドおよびその製造方法
DE69128283T2 (de) 1991-08-12 1998-03-19 Nestle Sa Nahrungsmittelzusammensetzung
US5308833A (en) * 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
AU5081193A (en) * 1992-08-31 1994-03-29 Magainin Pharmaceuticals, Inc. Treatment of gynecological malignancies with biologically active peptides
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
AU706333B2 (en) * 1993-09-24 1999-06-17 University Of Southern California Use of angiotensin III and analogs thereof in tissue repair
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
AU2473695A (en) * 1994-05-09 1995-11-29 Johns Hopkins University, The Method of slowing the progression of hiv infection
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
CZ262698A3 (cs) 1996-02-19 1999-03-17 Nycomed Imaging A/S Kontrastní prostředek pro zobrazování ultrazvukem a způsob jeho výroby
JPH09227590A (ja) * 1996-02-27 1997-09-02 Nisshin Flour Milling Co Ltd ペプチド
US5691314A (en) * 1996-03-18 1997-11-25 The Medical College Of Hampton Roads Adjunctive therapy
TW360501B (en) 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
ATE193636T1 (de) 1996-09-24 2000-06-15 Nestle Sa Milchaustauschprodukt und verfahren zu dessen herstellung
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
AU8333998A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
CA2319701C (en) * 1998-02-09 2009-09-29 University Of Southern California Method of promoting erythropoiesis
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
US6333313B1 (en) * 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
AU771034B2 (en) 1998-11-24 2004-03-11 Societe Des Produits Nestle S.A. Method for preparing a protein composition and an infant formula containing same
IL144359A0 (en) * 1999-01-21 2002-05-23 Vitro Diagnostics Inc Immortalized cell lines and methods of making the same
US20040013641A1 (en) 1999-04-15 2004-01-22 Monash University Disease prevention by reactivation of the thymus
US6313370B1 (en) * 1999-04-29 2001-11-06 Morton Hyson Medicated wrap
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2499211A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
AU2001257129A1 (en) * 2000-04-21 2001-11-07 Advanced Research And Technology Institute, Inc. Novel pharmacotherapeutic process and composition for central nervous system disorders
AU2001268326A1 (en) * 2000-06-14 2001-12-24 Chanda Zaveri Peptides with physiological activity
AU2001269439A1 (en) 2000-07-05 2002-01-14 Takeda Chemical Industries Ltd. Medicinal preparations for treating sex hormone-dependent diseases
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
AU2001282527A1 (en) * 2000-08-31 2002-03-13 Shionogi And Co., Ltd. Antiparkinsonism drugs
AU2001297873A1 (en) * 2000-11-21 2003-01-02 New England Medical Center Novel antimicrobial compounds
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
SE0100684D0 (sv) * 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
EP1389126B1 (en) * 2001-04-18 2016-12-21 The Regents of The University of California Retrocyclins: antiviral and antimicrobial peptides
SI1392348T1 (sl) * 2001-04-30 2008-12-31 Aeterna Zentaris Gmbh Zdravljenje demence in nevrodegenerativnih bolezni z antagonisti lhrh v vmesnih dozah
WO2002092018A2 (en) * 2001-05-16 2002-11-21 Plotnikoff Nicholas P Methods for inducing sustained immune response
WO2002096934A1 (en) * 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
SE0102910D0 (sv) * 2001-08-31 2001-08-31 Moberg Kerstin Uvnaes New use
WO2003020223A2 (en) * 2001-09-05 2003-03-13 James Lipton A cancer treatment system
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1314357B1 (en) 2001-11-23 2007-05-23 Société des Produits Nestlé S.A. Process for the preparation of milk powders and concentrated milk products
CA2391118A1 (en) * 2002-06-21 2003-12-21 Universite Du Quebec A Montreal Oxytocin as cardiomyogenesis inducer and uses thereof
US7655772B2 (en) * 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US20050008676A1 (en) * 2002-12-19 2005-01-13 Yongxing Qiu Medical devices having antimicrobial coatings thereon
JP2006524242A (ja) * 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
JP2007506730A (ja) * 2003-09-24 2007-03-22 ベクタ・リミテッド ペンタガストリンを含む胃酸分泌刺激用経口組成物
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US20070224165A1 (en) * 2003-10-23 2007-09-27 Neuren Pharmaceuticals Limited Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
US20070053954A1 (en) * 2003-10-24 2007-03-08 Rowe Stephen C Macromer-melt formulations
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
JP2007530697A (ja) * 2004-03-29 2007-11-01 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 両親媒性グリコペプチド
WO2005097161A2 (en) * 2004-03-30 2005-10-20 Neuren Pharmaceuticals Limited Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
WO2006068768A2 (en) * 2004-11-24 2006-06-29 Hanna Skubatch Methods and compositions for treating conditions
WO2006063596A2 (en) * 2004-12-15 2006-06-22 Aditech Pharma Ab A composition comprising pp for the treatment of gastrointestinal disorders
EP1845948A2 (en) * 2005-02-09 2007-10-24 DA Volterra Colonic delivery of active agents
US20060205642A1 (en) * 2005-03-08 2006-09-14 Vesely David L Oral methods of treatment using proANF peptides
ES2336826T3 (es) 2005-05-03 2010-04-16 Novetide, Ltd. Procedimientos para la produccion de un peptido que presenta una amida c-terminal.
JP2008545697A (ja) * 2005-05-23 2008-12-18 ニューレン ファーマシューティカルズ リミテッド グリシル−プロリル−グルタメートの類縁体
CA2620364A1 (en) * 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
AU2006290251B2 (en) * 2005-09-13 2011-12-08 Abburi Ramaiah Agonist peptides of basic fibroblast growth factor (BFGF) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing
US7601361B2 (en) * 2005-10-03 2009-10-13 E. I. Du Pont De Nemours And Company Process for providing antimicrobial surfaces
WO2007044998A1 (en) * 2005-10-12 2007-04-19 The Regents Of The University Of California Retrocyclins: antiviral and antimicrobial peptides
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CA2638773A1 (en) * 2006-01-24 2007-08-02 The University Of British Columbia Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects
PT1993515E (pt) 2006-03-10 2009-11-05 Laboswiss Ag Um método para solubilização, dispersão e estabilização de compostos, produtos obtidos por esse método, assim como a sua utilização
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
US20070238661A1 (en) * 2006-04-11 2007-10-11 Witten Mark L Substance P treatment for hepatitis C
WO2007134151A2 (en) * 2006-05-10 2007-11-22 Smithkline Beecham Corporation Composition and method for increasing cell permeability of a compound
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
CA2678131A1 (en) * 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2528094C2 (ru) * 2012-08-03 2014-09-10 Татьяна Георгиевна Емельянова Средство пептидной структуры, обладающее анальгетическим, противовоспалительным действием, и лекарственные формы на его основе

Also Published As

Publication number Publication date
WO2009039966A2 (en) 2009-04-02
RU2010113964A (ru) 2011-10-20
RU2010114033A (ru) 2011-10-20
WO2009033792A3 (en) 2009-08-13
WO2009043455A2 (en) 2009-04-09
JP2010539053A (ja) 2010-12-16
JP2010538977A (ja) 2010-12-16
RU2010113987A (ru) 2011-10-20
AU2008303945A1 (en) 2009-04-02
US8211856B2 (en) 2012-07-03
WO2009043528A1 (en) 2009-04-09
CA2699215A1 (en) 2009-03-19
AU2008306140A1 (en) 2009-04-09
US20100204148A1 (en) 2010-08-12
WO2009033802A3 (en) 2009-09-03
WO2009040006A1 (en) 2009-04-02
EP2187943A2 (en) 2010-05-26
WO2009046849A1 (en) 2009-04-16
EP2197480A2 (en) 2010-06-23
WO2009033658A1 (en) 2009-03-19
WO2009046834A3 (en) 2009-12-17
WO2009039981A2 (en) 2009-04-02
WO2009039966A3 (en) 2009-12-17
CA2699264A1 (en) 2009-04-09
JP2010538995A (ja) 2010-12-16
WO2009039980A3 (en) 2009-11-26
AU2008303942A1 (en) 2009-04-02
CA2699010A1 (en) 2009-03-19
CA2731204A1 (en) 2009-03-19
WO2009040030A1 (en) 2009-04-02
US20100210567A1 (en) 2010-08-19
CA2698821A1 (en) 2009-03-19
JP5384502B2 (ja) 2014-01-08
US20100273700A1 (en) 2010-10-28
WO2009033802A2 (en) 2009-03-19
RU2010113983A (ru) 2011-10-20
WO2009033678A2 (en) 2009-03-19
KR20100058558A (ko) 2010-06-03
CA2698764A1 (en) 2009-04-02
WO2009039980A2 (en) 2009-04-02
RU2010113965A (ru) 2011-10-20
AU2008297928A1 (en) 2009-03-19
WO2009039983A3 (en) 2009-05-28
WO2009046863A3 (en) 2009-06-25
EP2197469A2 (en) 2010-06-23
WO2009043437A3 (en) 2009-12-17
WO2009033793A2 (en) 2009-03-19
WO2009033793A3 (en) 2009-08-06
WO2009033792A2 (en) 2009-03-19
WO2009043437A2 (en) 2009-04-09
JP2010538989A (ja) 2010-12-16
AU2008297417A1 (en) 2009-03-19
AU2008303928A1 (en) 2009-04-02
WO2009033805A2 (en) 2009-03-19
CA2698768A1 (en) 2009-04-02
KR20100058547A (ko) 2010-06-03
EP2187919A1 (en) 2010-05-26
WO2009043455A3 (en) 2009-09-03
EP2205261A1 (en) 2010-07-14
EP2187951A2 (en) 2010-05-26
KR20100059860A (ko) 2010-06-04
JP2010538994A (ja) 2010-12-16
JP2010538987A (ja) 2010-12-16
WO2009033805A3 (en) 2009-09-03
KR20100057054A (ko) 2010-05-28
KR20100056508A (ko) 2010-05-27
KR20100075439A (ko) 2010-07-02
EP2190535B1 (en) 2012-08-08
WO2009046834A2 (en) 2009-04-16
US20100204143A1 (en) 2010-08-12
WO2009040084A3 (en) 2009-07-23
WO2009039983A2 (en) 2009-04-02
WO2009039981A3 (en) 2009-11-26
KR20100056509A (ko) 2010-05-27
EP2190535A2 (en) 2010-06-02
US20100190722A1 (en) 2010-07-29
WO2009040084A2 (en) 2009-04-02
RU2010114021A (ru) 2011-10-20
RU2010113975A (ru) 2011-10-20
US20100210534A1 (en) 2010-08-19
AU2008297948A1 (en) 2009-03-19
US20100286028A1 (en) 2010-11-11
JP2010539066A (ja) 2010-12-16
EP2187920A2 (en) 2010-05-26
US20100197572A1 (en) 2010-08-05
WO2009033678A3 (en) 2009-07-02
CA2699100A1 (en) 2009-04-02
WO2009046863A2 (en) 2009-04-16
AU2008297567A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
RU2010114001A (ru) Применение пептида в качестве терапевтического средства
RU2010114025A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114061A (ru) ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В КОМБИНАЦИИ С ПЕПТИДОМ Gly-Arg-Gly-Asp-Asn-Pro-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114028A (ru) Применение ангиотензина ii в качестве терапевтического средства, например, при инфекции s. pneumoniae
RU2010114009A (ru) Применение rgdspasskp и необязательно ангиотензина ii в качестве терапевтических средств при лечении, например, инфекций s. pneumoniae
RU2010114023A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113969A (ru) Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств
RU2010113985A (ru) Применение уродилатина в качестве терапевтического средства
RU2010113999A (ru) Применение секретина и необязательно уродилатина в качестве терапевтических средств
RU2010113974A (ru) Применение противовоспалительного пептида-1 в качестве терапевтического средства
RU2010114054A (ru) Применение пептида в качестве терапевтического средства
RU2010114010A (ru) Применение октреотида в качестве терапевтического средства
RU2010113979A (ru) Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv
RU2010114051A (ru) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
RU2010114030A (ru) Применение пептида в качестве терапевтического средства
RU2010114019A (ru) Минигастрин в качестве терапевтического средства
RU2010114003A (ru) Применение пептида фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114037A (ru) Применение белка полосы 3 и расар-27 в качестве терапевтического средства
RU2010114060A (ru) Применение пептида в качестве терапевтического средства

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110912